Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

查看全文 作　　者：S.;Aubrey;Stoch;Stefan;Zajic;Julie;A.;Stone;Deborah;L.;Miller;Lucas;Bortel;Kenneth;C.;Lasseter;Barnali;Pramanik;Caroline;Cilissen;Qi;Liu;Lida;Liu;Boyd;B.;Scott;Deborah;Panebianco;Yu;Ding;Keith;Gottesdiener;John;A.;Wagner